What are Maze Therapeutics, Inc. Common Stock's total assets?

Maze Therapeutics, Inc. Common Stock (MAZE) holds $419.7M in total assets, up 26.1% year over year.

How much debt does Maze Therapeutics, Inc. Common Stock have?

Maze Therapeutics, Inc. Common Stock carries $61.2M in total debt against $341.7M of shareholders' equity, a debt-to-equity ratio of 0.18.

How much cash does Maze Therapeutics, Inc. Common Stock have?

Maze Therapeutics, Inc. Common Stock holds $198.8M in cash and equivalents.

Can Maze Therapeutics, Inc. Common Stock cover its short-term obligations?

Its current ratio is 17.88 — current assets exceed current liabilities.

Where does Maze Therapeutics, Inc. Common Stock's balance sheet data come from?

Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Maze Therapeutics, Inc. Common Stock MAZE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$198.77M-32.5%	$189.25M-3.8%	$316.77M+112%	$264.54M+51.1%	$294.37M+880%
Short-term investments	$153.62M—	$152.67M—	$67.16M—	——	——
Restricted cash	$1.09M-0.1%	$1.09M0.0%	$1.09M—	$1.09M—	$1.09M—
Accounts receivable, net	$20M—	——	——	——	——
Prepaid expenses and other current assets	$7.4M+38.7%	$7.8M+60.5%	$7.37M—	$6.61M—	$5.33M+579%
Total current assets	$379.78M+26.7%	$349.72M+73.4%	$391.3M—	$271.15M—	$299.71M—
Property and equipment, net	$4.68M-25.8%	$5.04M-24.4%	$5.54M—	$6.01M—	$6.31M—
Operating lease right-of-use assets	$19.29M-14.2%	$20.12M-13.5%	$20.92M—	$21.71M—	$22.48M—
Other non-current assets	$4.32M+33.0%	$3.05M-61.2%	$3.21M—	$3.57M—	$3.25M—
Total assets	$419.71M+26.1%	$397.13M+65.1%	$422.06M—	$303.52M—	$332.84M—
Accounts payable	$4.01M+66.9%	$1.79M-7.5%	$2.92M+350%	$3.67M+847%	$2.4M+1,089%
Accrued expenses	$12.39M+7.3%	$15.97M+13.2%	$14.43M—	$11.52M—	$11.54M—
Current portion of long-term debt	$0—	——	——	——	——
Operating lease liabilities, current	$4.84M+3.5%	$4.8M+3.5%	$4.76M—	$4.72M—	$4.67M—
Total current liabilities	$21.24M+14.1%	$22.56M+9.1%	$22.11M—	$19.9M—	$18.62M—
Long-term debt	$38.83M—	——	——	——	——
Operating lease liabilities, non-current	$17.55M-17.0%	$18.51M-15.8%	$19.42M—	$20.29M—	$21.15M—
Operating Lease Liabilities (Total)	——	$23.31M—	——	——	——
Other non-current liabilities	$388K-61.4%	$1.09M+12.9%	$1.09M—	$1.09M—	$1.01M—
Total liabilities	$78.01M+91.3%	$42.16M-3.4%	$42.62M—	$41.28M—	$40.77M—
Preferred stock	$0—	$0—	$0—	$0—	——
Common stock	$50K+13.6%	$49K+2,350%	$48K—	$44K—	$44K—
Additional paid-in capital	$855.54M+25.2%	$844.35M+1,687%	$834.3M—	$687.09M—	$683.24M—
Retained earnings	-$513.76M-31.3%	-$489.55M-36.6%	-$454.98M—	-$424.89M—	-$391.21M—
Accumulated other comprehensive income (loss)	-$135K—	$110K—	$69K—	——	——
Total stockholders' equity	$341.7M+17.0%	$354.97M+214%	$379.44M—	$262.24M—	$292.07M—
Total liabilities and stockholders' equity	$419.71M+26.1%	$397.13M+65.1%	$422.06M—	$303.52M—	$332.84M—
Short- term Investments	$153.62M—	$152.67M—	$67.16M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$4.32M+33.0%	$3.05M-61.2%	$3.21M—	$3.57M—	$3.25M—
Net Investment in Lease	$19.29M-14.2%	$20.12M-13.5%	$20.92M—	$21.71M—	$22.48M—
Operating lease right-of-use assets	$19.29M-14.2%	$20.12M-13.5%	$20.92M—	$21.71M—	$22.48M—
Other non-current assets	$4.32M+33.0%	$3.05M-61.2%	$3.21M—	$3.57M—	$3.25M—
Operating Lease Right-of-Use Assets in Other Assets	$19.29M-14.2%	$20.12M-13.5%	$20.92M—	$21.71M—	$22.48M—
Software and Technology Licenses, Net	$4.32M+33.0%	$3.05M-61.2%	$3.21M—	$3.57M—	$3.25M—
Accrued expenses and other liabilities	$12.39M+7.3%	$15.97M+13.2%	$14.43M—	$11.52M—	$11.54M—
Total debt	$61.22M+137%	$23.31M-12.5%	$24.18M—	$25.01M—	$25.82M—
AOCI - Available-for-Sale Securities, Net of Tax	-$135K—	$110K—	$69K—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$50K+13.6%	$49K+2,350%	$48K—	$44K—	$44K—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Maze Therapeutics, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Maze Therapeutics, Inc. Common Stock's total assets?: Maze Therapeutics, Inc. Common Stock (MAZE) holds $419.7M in total assets, up 26.1% year over year.
How much debt does Maze Therapeutics, Inc. Common Stock have?: Maze Therapeutics, Inc. Common Stock carries $61.2M in total debt against $341.7M of shareholders' equity, a debt-to-equity ratio of 0.18.
How much cash does Maze Therapeutics, Inc. Common Stock have?: Maze Therapeutics, Inc. Common Stock holds $198.8M in cash and equivalents.
Can Maze Therapeutics, Inc. Common Stock cover its short-term obligations?: Its current ratio is 17.88 — current assets exceed current liabilities.
Where does Maze Therapeutics, Inc. Common Stock's balance sheet data come from?: Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.